Cargando…
Real-World Experience of Monitoring Practice of Endocrinopathies Associated with the Use of Novel Targeted Therapies among Patients with Solid Tumors
Background: Cancer treatments have gradually evolved into targeted molecular therapies characterized by a unique mechanism of action instead of non-specific cytotoxic chemotherapies. However, they have unique safety concerns. For instance, endocrinopathies, which are defined as unfavorable metabolic...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9680233/ https://www.ncbi.nlm.nih.gov/pubmed/36412906 http://dx.doi.org/10.3390/medsci10040065 |
_version_ | 1784834367255740416 |
---|---|
author | AlHarbi, Atika Alshamrani, Majed Khan, Mansoor Alnatsheh, Abdelmajid Aseeri, Mohammed |
author_facet | AlHarbi, Atika Alshamrani, Majed Khan, Mansoor Alnatsheh, Abdelmajid Aseeri, Mohammed |
author_sort | AlHarbi, Atika |
collection | PubMed |
description | Background: Cancer treatments have gradually evolved into targeted molecular therapies characterized by a unique mechanism of action instead of non-specific cytotoxic chemotherapies. However, they have unique safety concerns. For instance, endocrinopathies, which are defined as unfavorable metabolic alterations including thyroid disorders, hyperglycemia, dyslipidemia, and adrenal insufficiency necessitate additional monitoring. The aim of this study was to assess the prevalence of monitoring errors and develop strategies for monitoring cancer patients who receive targeted therapies. Method: A retrospective chart review was used to assess the prevalence of monitoring errors of endocrinopathies among cancer patients who received targeted therapies over one year. All of the adult cancer patients diagnosed with a solid tumor who received targeted therapies were included. The primary outcome was to determine the prevalence of monitoring errors of endocrinopathies. The secondary outcomes were to assess the incidences of endocrinopathies and referral practice to endocrinology services. Results: A total of 128 adult patients with solid tumors were involved. The primary outcome revealed a total of 148 monitoring errors of endocrinopathies. Monitoring errors of the lipid profile and thyroid functions were the most common error types in 94% and 92.6% of the patients treated with novel targeted therapies, respectively. Subsequently, 57% of the monitoring errors in the blood glucose measures were identified. Targeted therapies caused 63 events of endocrinopathies, hyperglycemia in 32% of the patients, thyroid disorders in 15.6% of them and dyslipidemia in 1.5% of the patients. Conclusion: Our study showed a high prevalence of monitoring errors among the cancer patients who received targeted therapies which led to endocrinopathies. It emphasizes the importance of adhering to monitoring strategies and following up on the appropriate referral process. |
format | Online Article Text |
id | pubmed-9680233 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-96802332022-11-23 Real-World Experience of Monitoring Practice of Endocrinopathies Associated with the Use of Novel Targeted Therapies among Patients with Solid Tumors AlHarbi, Atika Alshamrani, Majed Khan, Mansoor Alnatsheh, Abdelmajid Aseeri, Mohammed Med Sci (Basel) Article Background: Cancer treatments have gradually evolved into targeted molecular therapies characterized by a unique mechanism of action instead of non-specific cytotoxic chemotherapies. However, they have unique safety concerns. For instance, endocrinopathies, which are defined as unfavorable metabolic alterations including thyroid disorders, hyperglycemia, dyslipidemia, and adrenal insufficiency necessitate additional monitoring. The aim of this study was to assess the prevalence of monitoring errors and develop strategies for monitoring cancer patients who receive targeted therapies. Method: A retrospective chart review was used to assess the prevalence of monitoring errors of endocrinopathies among cancer patients who received targeted therapies over one year. All of the adult cancer patients diagnosed with a solid tumor who received targeted therapies were included. The primary outcome was to determine the prevalence of monitoring errors of endocrinopathies. The secondary outcomes were to assess the incidences of endocrinopathies and referral practice to endocrinology services. Results: A total of 128 adult patients with solid tumors were involved. The primary outcome revealed a total of 148 monitoring errors of endocrinopathies. Monitoring errors of the lipid profile and thyroid functions were the most common error types in 94% and 92.6% of the patients treated with novel targeted therapies, respectively. Subsequently, 57% of the monitoring errors in the blood glucose measures were identified. Targeted therapies caused 63 events of endocrinopathies, hyperglycemia in 32% of the patients, thyroid disorders in 15.6% of them and dyslipidemia in 1.5% of the patients. Conclusion: Our study showed a high prevalence of monitoring errors among the cancer patients who received targeted therapies which led to endocrinopathies. It emphasizes the importance of adhering to monitoring strategies and following up on the appropriate referral process. MDPI 2022-11-21 /pmc/articles/PMC9680233/ /pubmed/36412906 http://dx.doi.org/10.3390/medsci10040065 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article AlHarbi, Atika Alshamrani, Majed Khan, Mansoor Alnatsheh, Abdelmajid Aseeri, Mohammed Real-World Experience of Monitoring Practice of Endocrinopathies Associated with the Use of Novel Targeted Therapies among Patients with Solid Tumors |
title | Real-World Experience of Monitoring Practice of Endocrinopathies Associated with the Use of Novel Targeted Therapies among Patients with Solid Tumors |
title_full | Real-World Experience of Monitoring Practice of Endocrinopathies Associated with the Use of Novel Targeted Therapies among Patients with Solid Tumors |
title_fullStr | Real-World Experience of Monitoring Practice of Endocrinopathies Associated with the Use of Novel Targeted Therapies among Patients with Solid Tumors |
title_full_unstemmed | Real-World Experience of Monitoring Practice of Endocrinopathies Associated with the Use of Novel Targeted Therapies among Patients with Solid Tumors |
title_short | Real-World Experience of Monitoring Practice of Endocrinopathies Associated with the Use of Novel Targeted Therapies among Patients with Solid Tumors |
title_sort | real-world experience of monitoring practice of endocrinopathies associated with the use of novel targeted therapies among patients with solid tumors |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9680233/ https://www.ncbi.nlm.nih.gov/pubmed/36412906 http://dx.doi.org/10.3390/medsci10040065 |
work_keys_str_mv | AT alharbiatika realworldexperienceofmonitoringpracticeofendocrinopathiesassociatedwiththeuseofnoveltargetedtherapiesamongpatientswithsolidtumors AT alshamranimajed realworldexperienceofmonitoringpracticeofendocrinopathiesassociatedwiththeuseofnoveltargetedtherapiesamongpatientswithsolidtumors AT khanmansoor realworldexperienceofmonitoringpracticeofendocrinopathiesassociatedwiththeuseofnoveltargetedtherapiesamongpatientswithsolidtumors AT alnatshehabdelmajid realworldexperienceofmonitoringpracticeofendocrinopathiesassociatedwiththeuseofnoveltargetedtherapiesamongpatientswithsolidtumors AT aseerimohammed realworldexperienceofmonitoringpracticeofendocrinopathiesassociatedwiththeuseofnoveltargetedtherapiesamongpatientswithsolidtumors |